SICHUAN HUIYU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.24 CNY | +2.45% |
|
+2.74% | -5.88% |
| 05-15 | China Grants Drug Registration for Huiyu Pharma's Two Injectables | MT |
| 04-26 | Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 14,246 | 6,604 | 6,409 |
| Enterprise Value (EV) 1 | 11,298 | 4,077 | 4,269 |
| P/E ratio | 28 x | 26.4 x | 45.8 x |
| Yield | 0.63% | 1.51% | 1.41% |
| Capitalization / Revenue | 7.81 x | 4.42 x | 6.91 x |
| EV / Revenue | 6.19 x | 2.73 x | 4.6 x |
| EV / EBITDA | 24.1 x | 22.2 x | 66.9 x |
| EV / FCF | -77,156,233 x | -11,657,586 x | -16,175,081 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 4 x | 1.78 x | 1.7 x |
| Nbr of stocks (in thousands) | 423,600 | 423,600 | 423,600 |
| Reference price 2 | 33.63 | 15.59 | 15.13 |
| Announcement Date | 06/04/22 | 05/04/23 | 26/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 54.32 | 707.1 | 1,364 | 1,824 | 1,493 | 927.1 |
| EBITDA 1 | -33.96 | 224.6 | 403.1 | 468.9 | 183.3 | 63.8 |
| EBIT 1 | -55.95 | 206.2 | 378.4 | 433.5 | 136.5 | 6.388 |
| Operating Margin | -103% | 29.16% | 27.74% | 23.77% | 9.14% | 0.69% |
| Earnings before Tax (EBT) 1 | -71.33 | 200.2 | 396.5 | 477.7 | 238.4 | 132.2 |
| Net income 1 | -22 | 176.9 | 343.3 | 445.9 | 249 | 139.8 |
| Net margin | -40.51% | 25.02% | 25.17% | 24.45% | 16.67% | 15.08% |
| EPS | - | - | 0.9500 | 1.200 | 0.5900 | 0.3300 |
| Free Cash Flow | - | 37.78 | 114.3 | -146.4 | -349.8 | -263.9 |
| FCF margin | - | 5.34% | 8.38% | -8.03% | -23.42% | -28.47% |
| FCF Conversion (EBITDA) | - | 16.82% | 28.36% | - | - | - |
| FCF Conversion (Net income) | - | 21.35% | 33.3% | - | - | - |
| Dividend per Share | - | - | - | 0.2110 | 0.2350 | 0.2130 |
| Announcement Date | 26/09/21 | 26/09/21 | 26/09/21 | 06/04/22 | 05/04/23 | 26/04/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 99.2 | - | - | - | - | - |
| Net Cash position 1 | - | 397 | 600 | 2,948 | 2,527 | 2,140 |
| Leverage (Debt/EBITDA) | -2.921 x | - | - | - | - | - |
| Free Cash Flow | - | 37.8 | 114 | -146 | -350 | -264 |
| ROE (net income / shareholders' equity) | - | 137% | 58.9% | 20.7% | 6.84% | 3.72% |
| ROA (Net income/ Total Assets) | - | 21.5% | 22.8% | 10.1% | 2.03% | 0.09% |
| Assets 1 | - | 823.3 | 1,505 | 4,396 | 12,269 | 156,886 |
| Book Value Per Share | - | - | 2.090 | 8.400 | 8.780 | 8.900 |
| Cash Flow per Share | - | - | 1.030 | 3.080 | 2.850 | 4.210 |
| Capex 1 | 23 | 110 | 158 | 433 | 462 | 297 |
| Capex / Sales | 42.41% | 15.56% | 11.6% | 23.77% | 30.91% | 32.01% |
| Announcement Date | 26/09/21 | 26/09/21 | 26/09/21 | 06/04/22 | 05/04/23 | 26/04/24 |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -5.88% | 833M | |
| +40.73% | 739B | |
| +31.60% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +14.58% | 240B | |
| +9.44% | 210B | |
| -4.91% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 688553 Stock
- Financials Sichuan Huiyu Pharmaceutical Co., Ltd.
